All Hong Kong stocks quotes are at least 15 minutes delayed.
02591
INNOGEN-B
HKD
29.800-1.660
(-5.28%)
1D
AI Analysis
High
32.400
Open
32.400
VWAP
31.00
Vol
2.00M
Mkt Cap
19.00B
Low
29.680
Amount
47.00M
EV/EBITDA(TTM)
--
Total Shares
462.00M
EV
2.00B
EV/OCF(TTM)
--
P/S(TTM)
--
Guangzhou Innogen Pharmaceutical Group Co Ltd is a China-based investment holding company principally engaged in the research, development and commercialisation of pharmaceutical products. The Company is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The Company is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The Company principally conducts its businesses in the domestic market.
Show More
News
Money Flow
Over the past 66 trading days, overall net money flow is -62.00M, with retail investors contributing 1.00M and major investors adding -61.00M.
Net Buy $ Volume
Net Sell $ Volume

No data
Valuation Metrics
Forward PE

N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
AI Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly

No data

No data
People Also Watch




